Botulism Pipeline Landscape Analysis: 4+ Key Players & 5+ Pipeline Drugs

November 16 21:18 2022
Botulism Pipeline Landscape Analysis: 4+ Key Players & 5+ Pipeline Drugs

DelveInsight’s, “Botulism Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Botulism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


In the Botulism Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Botulism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


Key takeaways from the Botulism Pipeline Report

  • DelveInsight’s Botulism Pipeline analysis depicts the space with 4+ active players working to develop 5+ pipeline therapies.
  • Botulism Pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Botulism Pipeline Companies included XOMA, CytoDel, AlphaVax, PanThera Biopharma, and many others.
  • Botulism Pipeline Therapies included Biodefence vaccines, NTM-1633, and many others


Get to know more in-depth information about the Botulism Pipeline Report, click here: Botulism Pipeline Landscape


Botulism Overview

Botulism is a rare, naturally occurring disease that is caused by botulinum toxins from bacteria called Clostridium botulinum. It is transmitted through food, contact with contaminated soil, or through an open wound. The symptoms of Botulism include constipation, drooping eyelids, paralysis, difficulty swallowing or speaking, facial weakness on both sides of the face, blurred vision, trouble breathing, nausea, vomiting, and abdominal cramps (only in foodborne botulism). A diagnosis of Botulism is made based upon a thorough physical examination, a detailed patient history, and a variety of specialized tests. The standard test is a brain scan, cerebrospinal fluid examination, electromyography, and/or edrophonium chloride test for myasthenia gravis. Early diagnosis with foodborne or wound botulism can be cured with antitoxin. The antitoxin attaches itself to toxin that’s still circulating in bloodstream. In infants, a treatment known as botulism immune globulin blocks the actions of neurotoxins circulating in the blood. If the infection results from a wound, the wound needs to be treated surgically.


Recent Developmental Activities in the Botulism Pipeline            

  • NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). The therapy is currently under Phase-I clinical development for the treatment of botulism.
  • AlphaVax is developing immunostimulants as biodefence vaccines using Alphavaccine Platform System. The system is genetically derived from a modified alphavirus. The re-engineered alphavaccine particles express the substituted gene (or genes), rather than producing more virus particles, thereby transforming the original virus into a highly effective vaccine system. Alphavaccines is currently in preclinical development for the treatment of botulism.


Botulism Emerging Drugs

  • Biodefence vaccines: AlphaVax
  • NTM-1633: XOMA


Learn more about the emerging Botulism pipeline therapies @ Botulism Clinical Trials


Botulism Pipeline Therapeutic Analysis

There are approx. 4+ key companies which are developing therapies for Botulism. The companies which have their Botulism drug candidates in the most advanced stage, i.e. Phase I include, XOMA.


Scope of the Botulism Pipeline Report

  • Coverage- Global
  • Botulism Pipeline Companies included XOMA, CytoDel, AlphaVax, PanThera Biopharma, and many others.
  • Botulism Pipeline Therapies included Biodefence vaccines, NTM-1633, and many others
  • Botulism Preclinical and Discovery Stage Products
  • Botulism Inactive Products
  • Botulism Market Drivers and Barriers
  • Botulism Future Perspectives and Conclusion
  • Botulism Analyst Views


Table of Content

  1. Introduction
  2. Executive Summary
  3. Botulism: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Botulism – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Mid Stage Products (Phase II)
  10. Drug name: Company name
  11. Early Stage Products (Phase I)
  12. NTM-1633: XOMA
  13. Preclinical/Discovery Stage Products
  14. Biodefence vaccines: AlphaVax
  15. Inactive Products
  16. Botulism Key Companies
  17. Botulism Key Products
  18. Botulism- Unmet Needs
  19. Botulism- Market Drivers and Barriers
  20. Botulism- Future Perspectives and Conclusion
  21. Botulism Analyst Views
  22. Appendix


Got Queries? Reach out for more information @ Botulism Drugs & Companies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author